Docetaxel and Vinorelbine Plus Filgrastim in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Part of paid clinical trials in Modesto, California.
- Sponsor
- Amgen
- Study ID
- NCT00006215
- Phase
- PHASE2
- Status
- Unknown
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- filgrastim — BIOLOGICAL
- docetaxel — DRUG
- vinorelbine tartrate — DRUG
Study Details
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus filgrastim in treating patients who have stage IIIB or stage IV non-small cell lung cancer.
Key Dates
- Start date
- Oct 31, 1999
- Status verified
- Dec 2001
Study Design
- Primary purpose
- TREATMENT
Locations (19)
Find similar trials in Modesto, CA
By condition
By specialty
By research site
Gould Medical Group· Modesto, CASibley Memorial Hospital· Washington D.C., DCVeterans Affairs Medical Center - Washington, DC· Washington D.C., DCGeorgia Cancer Treatment Center, P.C.· Riverdale, GAOncology and Hematology Associates· Westwood, KSVeterans Affairs Medical Center - Brooklyn· Brooklyn, NY
Related Studies
- Lung Cancer Biomarkers and ScreeningRecruiting · NYU Langone Health · New York, New York
- Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung CancersRecruiting · Stanford University · Stanford, California
- Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung CancerRecruiting · Vanderbilt-Ingram Cancer Center · Nashville, Tennessee
- Molecular Predictors of Cancer in Patients at High Risk of Lung CancerRecruiting · Vanderbilt-Ingram Cancer Center · Nashville, Tennessee